Pre-operative volume reduction of locally advanced breast cancers (LABC) is an issue of great importance when approaching elderly women, who often present with extensive disease along with a burden of co-morbidity which increases the risk of complications and mortality from treatment. A comprehensive geriatric evaluation is a necessary requirement before recommending any treatment in older patients.
Breast cancer is the most common type of cancer in the female population worldwide, with an estimated incidence of more than 1.3 million new cases and 458,000 deaths in 2008. 1 Up to 30 % of breast cancers are reported to occur in women aged 70 years or over; 2, 3 however, due to the under-representation of elderly patients in cancer clinical trials, 4, 5 there are few data to help define the optimum treatment for these patients.
A retrospective study of trials submitted to the US Food and Drug Administration (FDA) for drug approval in the years [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] showed that the percentage of women aged 65 years and over enrolled in clinical trials of hormonal therapy for breast cancer closely matched the proportion of breast cancer patients of the same age in the US, but inclusion rates in chemotherapy trials are much lower. 6 Although the elderly population is heterogeneous, 65 years does not seem to be the optimum threshold for defining an elderly patient, and most of the members of a National Comprehensive Cancer Network (NCCN) taskforce for breast cancer in the elderly agreed to set 70 years as a better cut-off point. 7 Locally advanced breast cancer (LABC) refers to patients diagnosed with large primary cancers and/or regional adenopathy. Its frequency has diminished greatly thanks to screening mammography and early detection. However, there are some populations, such as women in low-income countries or elderly women in industrialised countries, who continue to experience disproportionately high breast cancer mortality rates, as they are at an increased risk of having locally advanced disease at diagnosis. Data show that the frequency of LABC is indeed higher in elderly women, with 10 % of cases occurring in patients younger than 40 years but 30 % occurring in patients aged 70 years or over. [8] [9] [10] In oestrogen receptor-positive (OR+) tumours, hormonal therapy has been shown to have only minor toxicity and similar activity compared to chemotherapy, 11 Tamoxifen has been the mainstay of endocrine therapy for OR+ breast cancer for more than 30 years, beyond being the first drug to be used in the neoadjuvant setting for elderly or frail patients unable to undergo surgery or more toxic therapies. [13] [14] [15] trial, they have been shown to be biologically equivalent, as neoadjuvant treatment, to tamoxifen. 20 Although there are no statistical differences in overall survival (OS) between tamoxifen and AIs, 21, 22 progression-free survival (PFS) is better in patients who have been treated with an AI. 23, 24 Several trials have assessed the efficacy and safety of neoadjuvant endocrine therapy using AIs in post-menopausal patients with breast cancer. Trials considering the three available drugs are discussed below under the relevant drug. Activity data for the AIs used in these trials are presented in Table 1 Results do reinforce the hypothesis that AIs may be more effective than tamoxifen in the treatment of OR+ early breast cancer that also overexpresses HER2, and the lack of significance could be due to the small patient numbers and underpowered design of the study.
Aromatase Inhibitors as Neoadjuvant Treatment in Elderly Patients with LABC
irreversible steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It is administered orally. Primary use of exemestane has been evaluated in several studies, mainly Phase II trials. [40] [41] [42] [43] Overall response rates are consistently high, with more than two-thirds of patients worldwide experiencing partial responses.
In a small Phase II trial with in vivo correlative studies, it was demonstrated that neoadjuvant exemestane causes shrinkage of tumours in more than 80 % of patients, along with markedly reducing cellular proliferation and progesterone receptor expression. 18 In the German neoadjuvant Aromasin ® initiative (GENARI) trial, patients with a median age of 71 years received exemestane for four months prior to surgery. Overall response rates were about 40 %, and more than half the patients were eventually treated with BCS. 44 The most frequently reported toxicity was hot flushes.
In a French study, patients with a median age of 67 years were given exemestane for 4-5 months prior to surgery. 45 In this study, more than two-thirds of patients experienced a response. BCS was performed in 31 (45.2 %) patients. No grade 3 or 4 toxicities were observed.
In a Russian study, exemestane was compared with tamoxifen. One hundred and fifty-one women with hormone receptor-positive breast cancer were randomised to receive either tamoxifen or exemestane for three months. 46 While the clinical ORR was greater for exemestane In a recently published Spanish Phase II trial, 47 55 patients with OR+ breast cancer ineligible for BCS at baseline (mean age 76 years) were recruited to receive oral exemestane 25 mg daily for six months. An Italian study by Mustacchi et al. 40 specifically looked at elderly patients. The median age of the 117 patients enrolled was 80 years.
The overall response rate, assessed by means of either clinical and radiological or clinical-only evaluation, was 69.6 %. Surgery was then performed in two-thirds of patients.
Comprehensive Geriatric Assessment
There is general agreement that evaluation of breast cancer-related mortality risk and of other patient-related factors, such as functional status, co-morbidities, cognition and psychosocial issues, is to be assessed to individualise treatment for older patients.
Comprehensive geriatric assessment (CGA) is a multidisciplinary evaluation of the older patient which allows identification and classification of clinical/functional conditions in elderly patients, integrating information on various domains such as disability, co-morbidity, cognitive status, presence of depression, social and economic status and other conditions which may influence the global health status of elderly subjects, in order to develop a comprehensive plan of assistance and treatment which takes into account the effective needs of older patients 51 and their expectations. 52 Breast Cancer According to the CGA, patients may be classified into three main groups:
• 'fit' patients, which includes subjects presenting no limitation in activities of daily living (ADLs) and with no major co-morbidity, who present rough mortality rates at two years of 8-12 %;
• 'frail' patients, who are patients older than 85 years or those presenting with severe co-morbidity or functional dependence in ADLs, or with geriatric syndromes (dementia, delirium, severe osteoporosis, depression, failure to thrive, inability to gain weight, falls, incontinence), with mortality rates higher than 40 %; and
• In between are the majority of elderly patients defined as 'vulnerable', who are dependent in some instrumental activities of daily living (IADLs), but not in ADLs, or who present manageable co-morbidity with appropriate treatment; their mortality rates are approximately 16-25 % at two years. 53 Generally, elderly patients who are deemed frail at the CGA have a rough two-year mortality of 40 % independently of the diagnosis of cancer; therefore recommendations have been made to deliver only best supportive care. 53 Several studies on CGA show that for patients with breast cancer functional status is indeed a predictive factor for survival, for mortality and for toxicity from treatments. 54, 55 Severe osteoporosis or severe dyslipidaemia may in some cases contraindicate treatment with AIs. CGA, and in particular careful detection of co-morbidity, could be a useful tool in such cases for selection of patients that could derive benefit from endocrine treatment with tamoxifen instead of AIs.
Given these considerations, the approach to older adults with breast cancer must include a multidimensional comprehensive geriatric evaluation in order to unveil potential weakness that may result in severe toxicity or complications from treatment and to maximise benefits. 56 On this view, endocrine therapy may be a good option for those patients having large OR/PR+ breast tumours in which immediate surgery may lead to functional impairment or may be contraindicated, and chemotherapy may result in unacceptable toxicities.
Treatment duration -Primary and Definitive Treatment
A critical question about neoadjuvant treatment with an AI is for how long to treat in the pre-operative setting. To date, there is no defined median treatment duration.
Usually, neoadjuvant endocrine treatment is prolonged for 3-4 months before surgery. 11, 23, 25, 32, 38, 39, 45, 47, 48 According to the study by Krainick-Strobel et al., a minimum of four months of therapy is necessary, yet a longer duration of treatment may lead to better results. In this study, which specifically addressed the question of pre-operative treatment duration, 32 patients were treated with letrozole 2.5 mg orally daily for 4-8 months and clinical and radiological tumour response was evaluated. Unfortunately, the trial was stopped prematurely due to slow recruitment, but available data support the consideration that prolonged treatment for up to eight months rather than an early interruption after four months can result in further tumour volume reduction in some patients. 48 To date, conclusive data on the optimal duration of pre-operative endocrine treatments for OR/PR+ breast cancer in post-menopausal women are still not available.
Recommendation from the panel of experts at the St Gallen consensus conference held in 2011 are for the continuation of treatment until maximum response is obtained, or for a minimum of 4-8 months. 57 In some cases, given the high response rate reached with AIs, some elderly patients (≥70 years old) may be spared surgery. A review of seven randomised trials showed no difference in OS for patients undergoing primary endocrine therapy with tamoxifen when compared with surgery, with or without tamoxifen. 28 However, the patients who underwent surgery experienced a lower rate of relapse; therefore a recommendation can be made that primary endocrine therapy with tamoxifen should be suggested if patients are unfit for surgery. However, only scarce data are available for primary, definitive treatment with third-generation AIs.
In most of the studies of neoadjuvant endocrine treatment, the majority of patients were then treated with surgery. 23, 58 However, there are some data from retrospective studies specifically addressed to elderly patients in which response rates with the use of AIs as neoadjuvant treatment are fairly high and survival rates are quite encouraging, despite the fact that surgery was performed only in a minority of cases. 49, 50 In a small Scottish study, 50 most patients were deemed frail and therefore not candidates for surgery. However, PFS rates were 65 % and 43 %, respectively, at 2 and 5 years from beginning of treatment with letrozole, with OS at 2 years of 76 %, at 5 years of 32 %.
In an Italian study by Brunello et al., 49 a large proportion of patients (57.6 %) were deemed frail following the CGA; at two and five years, PFS rates were 95 % and 85 % and OS rates were 95 % and 64 %, respectively. Less than half received further antineoplastic treatments and only with endocrine drugs. In this study, surgery was eventually performed in 10 % of patients only.
A possible suggestion is therefore that, depending on the results of CGA, surgery may be omitted without significantly compromising PFS and OS in frail or unfit patients.
Conclusions
Since the optimal endocrine treatment schedule remains to be determined, prospective observational and randomised studies are needed to better assess not only the clinical benefit of neoadjuvant treatment with AIs but also resistance which may develop in case it is administered as 'definitive' treatment. Furthermore, possible risks correlated with long-term use such as osteoporosis, which could affect morbidity and mortality beyond oncological disease, need to be investigated. 59 In the effort to optimise treatment for elderly patients, we should promote the conduction of such studies specifically addressed to the elderly using standardised tools of assessment in order to weigh 
